CATALOGO DEI PRODOTTI DELLA RICERCA

MELISI, Davide
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.079
EU - Europa 7.143
AS - Asia 5.522
SA - Sud America 723
Continente sconosciuto - Info sul continente non disponibili 202
AF - Africa 150
OC - Oceania 17
Totale 21.836
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.915
RU - Federazione Russa 2.759
SG - Singapore 2.133
CN - Cina 1.810
GB - Regno Unito 1.251
IT - Italia 811
BR - Brasile 565
SE - Svezia 515
VN - Vietnam 488
HK - Hong Kong 469
DE - Germania 447
FR - Francia 368
IE - Irlanda 367
FI - Finlandia 259
KR - Corea 175
CA - Canada 93
UA - Ucraina 84
BD - Bangladesh 82
IN - India 68
NL - Olanda 61
AR - Argentina 58
JP - Giappone 48
TR - Turchia 43
MX - Messico 39
NG - Nigeria 36
ZA - Sudafrica 36
AT - Austria 35
PL - Polonia 34
ES - Italia 30
ID - Indonesia 29
IQ - Iraq 24
EC - Ecuador 22
BE - Belgio 21
SA - Arabia Saudita 20
VE - Venezuela 18
CL - Cile 17
PK - Pakistan 17
PY - Paraguay 17
TG - Togo 17
AU - Australia 16
BJ - Benin 15
CH - Svizzera 15
JO - Giordania 15
MA - Marocco 15
PH - Filippine 14
UZ - Uzbekistan 13
CO - Colombia 12
CZ - Repubblica Ceca 12
LT - Lituania 12
PT - Portogallo 11
IR - Iran 8
MY - Malesia 8
DZ - Algeria 7
PE - Perù 7
AE - Emirati Arabi Uniti 6
KE - Kenya 6
NP - Nepal 6
AL - Albania 5
AZ - Azerbaigian 5
JM - Giamaica 5
KG - Kirghizistan 5
RO - Romania 5
UY - Uruguay 5
BG - Bulgaria 4
BY - Bielorussia 4
EE - Estonia 4
EG - Egitto 4
EU - Europa 4
GR - Grecia 4
HN - Honduras 4
HU - Ungheria 4
KZ - Kazakistan 4
LK - Sri Lanka 4
NO - Norvegia 4
PA - Panama 4
QA - Qatar 4
SN - Senegal 4
AM - Armenia 3
CR - Costa Rica 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
GE - Georgia 3
HR - Croazia 3
IL - Israele 3
LB - Libano 3
TT - Trinidad e Tobago 3
BO - Bolivia 2
CI - Costa d'Avorio 2
KH - Cambogia 2
LV - Lettonia 2
NI - Nicaragua 2
OM - Oman 2
PR - Porto Rico 2
PS - Palestinian Territory 2
RS - Serbia 2
TH - Thailandia 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
Totale 21.617
Salva come PNG Salva come JPEG
Città #
Singapore 1.107
Southend 1.033
Ashburn 1.025
Moscow 933
Chandler 841
San Jose 765
Dallas 634
Jacksonville 491
Hong Kong 466
Woodbridge 400
Dublin 365
Verona 309
Beijing 283
Council Bluffs 283
The Dalles 278
Ann Arbor 268
Ho Chi Minh City 179
Jinan 162
Houston 140
New York 134
Lawrence 132
Princeton 132
Los Angeles 130
Wilmington 129
Munich 122
Shenyang 97
Hanoi 94
Nanjing 89
Helsinki 82
Tianjin 78
Buffalo 74
Hebei 66
Santa Clara 66
São Paulo 60
Milan 58
Columbus 55
Redondo Beach 54
Changsha 53
Zhengzhou 47
Sindelfingen 45
Haikou 44
Frankfurt am Main 43
Turku 42
Orem 41
Chicago 39
Taiyuan 39
Tokyo 39
Hangzhou 38
London 37
Guangzhou 36
Rome 36
Redwood City 35
Abuja 34
Nanchang 31
Ningbo 31
Taizhou 31
Toronto 29
Montreal 28
Atlanta 27
Seattle 27
Johannesburg 26
Warsaw 26
Washington 26
Fuzhou 25
Da Nang 23
Nuremberg 23
Phoenix 23
Rio de Janeiro 23
San Francisco 23
Amsterdam 22
Boardman 22
Boston 22
Denver 22
Redmond 22
Brooklyn 21
Kent 21
Brussels 20
Dong Ket 20
Jiaxing 20
Jakarta 19
Bologna 18
Vienna 18
Lomé 17
Norwalk 17
Bar Harbor 16
Barnet 16
Brasília 16
Seoul 16
Belo Horizonte 15
Cotonou 15
Haiphong 15
Mexico City 15
Stockholm 15
Amman 14
Chennai 14
Dongguan 14
Lanzhou 13
Mumbai 13
Zurich 13
Ankara 12
Totale 13.217
Salva come PNG Salva come JPEG
Nome #
An FGFR3 autocrine loop sustains acquired resistance to trastuzumab in gastric cancer patients 318
A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma 293
Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatment 261
Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. 261
A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial 253
Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling 238
Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma 235
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups 221
NF-κB as a target for pancreatic cancer therapy. 217
Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer 208
A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial 205
A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer 202
Correlation of MR features and histogram-derived parameters with aggressiveness and outcomes after resection in pancreatic ductal adenocarcinoma 202
Induction of immunosuppressive functions and NF-κB by FLIP in monocytes 197
Current Strategies to Overcome Resistance to ALK-Inhibitor Agents 195
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 195
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients 195
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 193
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy 190
An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis 190
Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance 187
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 186
A novel modified CpG agonist of TLR-9 inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan eradicating colon cancer xenografts 186
Pancreatic ductal adenocarcinoma cell lines display a plastic ability to bi‑directionally convert into cancer stem cells 186
Plasma Interleukin-8 is a biomarker for TAK1 activation and predicts resistance to nanoliposomal irinotecan in patients with gemcitabine-refractory pancreatic cancer 186
Data demonstrating the role of peroxiredoxin 2 as important anti-oxidant system in lung homeostasis. 185
A selective cyclooxygenase-2 inhibitor combined with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') and protein kinase A antisense causes cooperative tumor growth inhibition after oral administration 184
Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo 184
Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. 183
Anti- VEGF treatment resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype 180
The development of PARP as a successful target for cancer therapy 180
Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer 180
Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results 178
Modulating TAK1 expression inhibits YAP and TAZ oncogenic functions in pancreatic cancer 176
Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma 175
Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients 175
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients 174
Adjuvant chemotherapy is associated with improved postoperative survival in specific subtypes of invasive intraductal papillary mucinous neoplasms (IPMN) of the pancreas: it is time for randomized controlled data 174
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib 174
PEROXIREDOXIN-2: A NOVEL REGULATOR OF IRON HOMEOSTASIS IN INEFFECTIVE ERYTHROPOIESIS 171
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study 170
Pancreatic Cancer: between bench and bedside. 170
AGENTI BIOLOGICI e CHEMIOTERAPICI: INTEGRAZIONE 169
TGF-beta-activated Kinase 1 (TAK1) is a therapeutic target modulating pancreatic cancer chemoresistance 166
CT texture analysis of ductal adenocarcinoma downstaged after chemotherapy 165
Histogram analysis of magnetic resonance images: evaluation of intra-tumoral heterogeneity and correlation with pathological findings in solid pancreatic tumors. 165
EMT and Treatment Resistance in Pancreatic Cancer 164
Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients 164
ESGAR 2018 Book of Abstracts 163
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 160
Targeting KRAS: The Elephant in the Room of Epithelial Cancers 159
Angiogenesis: A target for cancer therapy. 158
From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer 158
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 157
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? 157
MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity 156
Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion 156
Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy 155
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research 155
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities 154
A novel modified CpG inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan in colon cancer xenografts. 153
Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma 152
Pro-inflammatory factors secreted by pancreatic cancers with evasive resistance to anti-VEGF treatment contribute to malignant progression by inducing EMT 152
Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer 149
TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy 147
R1507, the human monoclonal antibody targeting the Insulin-like Growth Factor Receptor (IGF-1R), in combination with cetuximab can reverse acquired resistance to cetuximab in pancreatic and colon cancer models 146
Toll-Like Receptor 9 Agonists for Cancer Therapy 144
Peroxiredoxin-2 plays a pivotal role as multimodal cytoprotector in the early phase of pulmonary hypertension 142
Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation 142
Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial 141
Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma 140
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. 139
HOX Genes Family and Cancer: A Novel Role for Homeobox B9 in the Resistance to Anti-Angiogenic Therapies 136
Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversible by blood transfusion 135
Clinical Response to Futibatinib in Patients with High-Level FGFR2-Amplified Advanced Gastric Cancer: Two Case Reports 134
Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. 133
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 131
Novel Toll-like receptor 9 (TLR9) agonist IMO inhibits tumor growth and cooperates with cetuximab in K-Ras mutant colon and pancreatic cancer 130
Rare secondary tumors of the pancreas 130
Combination of a selective cyclooxygenase-2 inhibitor with EGFR tyrosine kinase inhibitor ZD1839 (‘Iressa’) and Protein Kinase A antisense causes a cooperative antitumor and antiangiogenic effect 129
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers 128
YAP Activation Is Associated with a Worse Prognosis of Poorly Cohesive Gastric Cancer 127
Injectable Thermogelling Nanostructured Ink as Simultaneous Optical and Magnetic Resonance Imaging Contrast Agent for Image-Guided Surgery 127
The Multifaceted Role of TGF-β in Gastrointestinal Tumors 126
Gefitinib ('Iressa, ZD1839') and a second generation antisense targeting murine double minute 2 (Mdm2) synergistically inhibit tumor growth and angiogenesis in hormone-refractory prostate cancer 125
Metastatic pancreatic cancer: Is there a light at the end of the tunnel? 125
The curious case of Gαs gain-of-function in neoplasia 125
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. 124
Human cancer cells with acquired resistance to anti-EGFR therapy are inhibited by VEGF- and EGFR-receptors tyrosine kinase inhibitor ZD6474 123
Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus 123
Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells 123
Targeting the epidermal growth factor receptor in solid tumors: focus on safety. 122
Permissive State of EMT: The Role of Immune Cell Compartment 122
Targeting transforming growth factor beta (TGFbeta) type I receptor kinase activity: a therapeutic approach to suppress metastatic processes in human pancreatic cancer (HPC) 121
TGF-beta activated kinase 1 (TAK1) is a drugable target for pancreatic cancer (PC) 121
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough 121
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. 120
LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. 120
Zoledronic acid (ZOMETA) in combination with a COX-2 inhibitor and gefitinb ('Iressa, ZD1839') cooperatively inhibits growth and angiogenic factor expression and secretion in breast and prostate carcinoma cells 120
Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy 120
Totale 16.562
Salva come PNG Salva come JPEG
Categoria #
all - tutte 79.234
article - articoli 68.136
book - libri 0
conference - conferenze 9.286
curatela - curatele 0
other - altro 501
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.311
Totale 158.468
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.134 0 433 13 167 15 15 9 62 38 22 68 292
2022/20232.311 180 234 221 357 209 553 28 138 293 23 49 26
2023/20241.331 43 101 94 123 164 183 116 166 15 71 198 57
2024/20253.233 167 191 110 510 138 99 177 160 491 200 311 679
2025/20269.200 686 430 685 1.424 2.274 625 894 487 733 568 173 221
2026/2027427 117 310 0 0 0 0 0 0 0 0 0 0
Totale 21.836